8082-737-676
Kalkine 0
countryflagUK
L

SMSN 969.0 0.7277% TYT 2786.5 4.8542% SMSD 810.0 0.4963% SMSN 964.0 0.2079% RIGD 65.3 2.9968% RIGD 63.4 5.6667% SHEL 2443.0 -0.6103% AZN 10618.0 0.874% BHP 1815.0 0.9455% HSBA 855.6 2.6268% ULVR 4687.0 -0.2554% CYPC 39.6 -2.4631% RIO 4546.5 0.4751% LLPC 1.548 -99.0% DGED 110.88 -0.1066% BP 353.2 -2.4309% SBID 95.4 0.0% DGE 2058.0 -0.5797% GSK 1432.0 1.6324% REL 4002.0 1.0606%
SMSN 969.0 0.7277% TYT 2786.5 4.8542% SMSD 810.0 0.4963% SMSN 964.0 0.2079% RIGD 65.3 2.9968% RIGD 63.4 5.6667% SHEL 2443.0 -0.6103% AZN 10618.0 0.874% BHP 1815.0 0.9455% HSBA 855.6 2.6268% ULVR 4687.0 -0.2554% CYPC 39.6 -2.4631% RIO 4546.5 0.4751% LLPC 1.548 -99.0% DGED 110.88 -0.1066% BP 353.2 -2.4309% SBID 95.4 0.0% DGE 2058.0 -0.5797% GSK 1432.0 1.6324% REL 4002.0 1.0606%

Home » Low-To-Medium Risk » Healthcare Report

Healthcare Report

The Healthcare Report includes Companies in the business of providing medical services, manufacturing drugs, producing medical devices, supplying medical insurance services, or any other company otherwise enabling patient care.

Get In Touch
  • Australia+61
  • Canada+1
  • India (भारत)+91
  • New Zealand+64
  • United Kingdom+44
  • United States+1
By submitting your details, you agree to Kalkine's Terms and Conditions and confirm that your are happy for one of our representatives to contact you to discuss our services. Your data will be processed in accordance with our Privacy Policy
Please wait processing your request...
  • Launch Date

    05-Dec-2019

  • Frequency

    Weekly

  • Suitable For

    Investor

  • Risk Rating

    Low-To-Medium Risk

  • @ GBP 888/ Year

Overview

  • The companies that have the potential to perform in short to long term are considered.
  • Broader industry dynamics are taken under consideration to provide a long-term outlook.
  • Certain risk factors such as regulatory concerns, market fluctuations, and other company specific risks are analyzed carefully.
  • Appropriate valuation methodology is applied to provide a holistic view on the company.
My alt text



Stay apprised, Invest wise with KALKINE!

Key Reasons to consider

Defensive Stocks

Health care stocks can be purely defensive play in an environment of rising interest rates and economic uncertainty.

Growth Catalysts

The healthcare sector is currently expanding and offering long-term success stories given the innovations at hand, new approvals falling in place with relaxed norms and prevailing positive trends globally.

Comprehensive Risk Analysis

While the defensive and diverse nature of the sector governs the momentum, one also needs to look at the challenges that are mainly associated with the government regulatory changes, increased competition, safety concerns, outcome of research trials, and

Stock Covered

Related Report

​Helios Underwriting PLC

Apr 17, 2025
Oxford Nanopore Technologies PLC

Apr 10, 2025
Smith & Nephew PLC

Apr 03, 2025
Hikma Pharmaceuticals PLC

Mar 27, 2025
NIOX Group PLC

Mar 20, 2025
Bioventix PLC

Mar 13, 2025
Animalcare Group PLC

Mar 06, 2025
GSK PLC

Feb 27, 2025
AstraZeneca PLC

Feb 20, 2025
Craneware PLC

Feb 13, 2025
Advanced Medical Solutions Group PLC

Feb 06, 2025
hVIVO PLC

Jan 30, 2025
PureTech Health PLC

Jan 23, 2025
GSK PLC

Jan 16, 2025
Oxford Nanopore Technologies plc

Jan 09, 2025
Spire Healthcare Group PLC

Dec 19, 2024
hVIVO PLC

Dec 12, 2024
Uniphar PLC

Dec 05, 2024
View All →

FAQs

The growth in aging population, people living longer with chronic disease, obesity and diabetes epidemics, technological advancements, the global reach of disease, personalized medicine, among others are the demand drivers.

Normal business environment after elevated demand induced by the Covid-19 pandemic can restrict the growth prospects. The sector can also be impacted by supply chain shortage, economic recession, fluctuating exchange rate movements, among others.

Healthcare Report

GBP 888/Year

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions